Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04765839 · ClinicalTrials.gov registry record · NA

Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations

A NA study of Vaccine Preventable Disease, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT04765839: Completed NA study of Vaccine Preventable Disease, sponsored by Mayo Clinic.

NCT04765839 is a NA study of Vaccine Preventable Disease that has completed, run by Mayo Clinic. The registered enrollment target is 74 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04765839, a NA study of Vaccine Preventable Disease, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants. At baseline, 2 weeks and 4 weeks, the study team will survey participants to assess knowledge and attitudes about COVID-19 vaccines, including intention to be vaccinated.

Primary Outcome

Related to perceived susceptibility and preventive measures will be assessed through 3 survey instruments, based on 7-point Likert scale.

Interventions

  • OTHER Educational, culturally appropriate COVID-19 messages

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2021-02-12
Est. Completion 2021-04-03
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT04765839 record still lists

NCT04765839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Vaccine Preventable Disease appearing as the primary indexed condition, and to 1 intervention - of which Educational, culturally appropriate COVID-19 messages is the first listed.

NCT04765839 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04765839 about?

NCT04765839 is a clinical study titled "Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations". A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants. At baseline, 2 weeks and 4 weeks, the study team will survey participants to assess knowledge and attitudes ...

What is the current status of trial NCT04765839?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2021-02-12. Estimated completion is 2021-04-03.

What conditions does trial NCT04765839 study?

This clinical trial studies the following conditions: Vaccine Preventable Disease.

What interventions are being tested in trial NCT04765839?

The interventions under investigation include: Educational, culturally appropriate COVID-19 messages (OTHER).

Who is sponsoring clinical trial NCT04765839?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04765839 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT04765839's enrollment target sits among peer trials

74 1082nd of 2000 higher than 912 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04765839, the US trial registry maintained by the National Library of Medicine. NCT04765839 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.